Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Live Oak Private Wealth LLC

Live Oak Private Wealth LLC boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,355 shares of the medical equipment provider's stock after purchasing an additional 5,369 shares during the quarter. Live Oak Private Wealth LLC's holdings in Zimmer Biomet were worth $6,039,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Garde Capital Inc. bought a new stake in Zimmer Biomet during the first quarter valued at about $29,000. Menard Financial Group LLC acquired a new stake in Zimmer Biomet in the fourth quarter worth about $30,000. Accredited Wealth Management LLC acquired a new stake in Zimmer Biomet in the fourth quarter worth about $36,000. OFI Invest Asset Management acquired a new stake in Zimmer Biomet in the fourth quarter worth about $40,000. Finally, FNY Investment Advisers LLC boosted its holdings in Zimmer Biomet by 90.5% in the first quarter. FNY Investment Advisers LLC now owns 400 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 190 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wells Fargo & Company lowered their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. The Goldman Sachs Group lowered their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Royal Bank Of Canada lowered their price target on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Finally, Raymond James Financial reduced their price objective on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $111.53.

Insider Activity

In other news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider now directly owns 20,424 shares in the company, valued at $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Stock Performance

ZBH stock traded up $0.29 during trading on Monday, hitting $91.51. 1,688,040 shares of the company traded hands, compared to its average volume of 1,795,537. The stock's 50-day simple moving average is $95.08 and its 200 day simple moving average is $102.64. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. The company has a market cap of $18.11 billion, a PE ratio of 20.25, a P/E/G ratio of 2.11 and a beta of 0.72. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. Zimmer Biomet's quarterly revenue was up 1.1% on a year-over-year basis. During the same period last year, the business earned $1.94 earnings per share. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.05%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.